LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

about

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

Item

http://www.wikidata.org/entity/Q57483685

description

im Jahr 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

@en

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

@nl

type

Item

label

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

@en

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

@nl

prefLabel

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

@en

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

@nl

P1476

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

@en

P2093

Andrea Rossi

http://www.w3.org/2001/XMLSchema#string

Fulvio Braido

http://www.w3.org/2001/XMLSchema#string

Girolamo Pelaia

http://www.w3.org/2001/XMLSchema#string

Luigino Calzetta

http://www.w3.org/2001/XMLSchema#string

Mario Cazzola

http://www.w3.org/2001/XMLSchema#string

Nicola Scichilone

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).

Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone pr

Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models.

Fluticasone propionate: a potent inhaled corticosteroid for the treatment of asthma.

β2-agonist therapy in lung disease.

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

P304

3115-3130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/COPD.S170606

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paola Rogliani

Enrico M. Clini

Fabiano Di Marco

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30323582

http://www.w3.org/2001/XMLSchema#string

P921

health policy

P932

6174911

http://www.w3.org/2001/XMLSchema#string